The U.S. Food and Drug Administration has accepted Novo Nordisk's marketing application for an oral version of its ...

Novo Nordisk’s oral Wegovy pill for chronic weight loss is under FDA review. If approved, it would be the first oral GLP-1 ...

Wegovy and Ozempic are both semaglutide weight loss medications, but they’re prescribed differently based on who qualifies.

Novo Nordisk A/S (NYSE: NVO) is seeking FDA approval for the pill version of its obesity drug, Wegovy. The company highlights ...

A new study analyzed how often people develop severe side effects after taking semaglutide — known by brand names Ozempic and ...

Rybelsus. Rybelsus is a daily pill FDA-approved for diabetes but sometimes prescribed off-label for weight loss. As with brand-name versions of semaglutide, there’s no magic number for how long ...

A decision is expected in the fourth quarter of 2025.

Rybelsus. Rybelsus is an oral form of semaglutide. It’s FDA-approved for diabetes, but (like Ozempic) it’s sometimes prescribed off-label for weight loss. Compounded semaglutide. Compounded ...

The FDA has accepted for review the New Drug Application for a 25mg oral formulation of semaglutide for chronic weight management.

Weight-loss surgeries for adolescents increased 15% in the U.S. between 2021 and 2023, even as the Food and Drug ...

While they share similarities, there are differences, particularly between the drugs semaglutide and tirzepatide.